Cempra, Toyama milestone payment

Cempra received a $10 million milestone payment from Toyama under a 2013 deal granting Toyama exclusive rights to develop and commercialize solithromycin in Japan. The payment was triggered by the start of a Japanese Phase III trial of the fluoroketolide/macrolide antibiotic to treat community-acquired bacterial pneumonia (CABP). Under the deal, Cempra is eligible for up to a further $30 million in milestones, plus tiered royalties. Toyama is a subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan) (see BioCentury, May 20, 2013). ...